Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to seven new employees as employment inducement awards. The options total 204,163 shares with an exercise price of $2.73 per share, matching the closing price on September 30, 2025.
The options feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia. The grants were made under Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has awarded stock options to two new employees as employment inducement grants. The options total 95,100 shares of common stock with an exercise price of $3.14 per share, matching the closing price on August 29, 2025.
The options feature a four-year vesting schedule, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are governed by Akebia's inducement award program and stock option agreements.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in September 2025. The company's executives will present at the Wells Fargo Healthcare Conference in Boston (September 3-5) and the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10).
Chief Financial and Chief Business Officer Erik Ostrowski and Chief Commercial Officer Nik Grund will lead both presentations. The Wells Fargo presentation is scheduled for September 4 at 8:00 AM EDT, while the H.C. Wainwright fireside chat will take place on September 8 at 12:00 PM EDT. Webcasts will be available through Akebia's investor relations website.
Akebia Therapeutics (Nasdaq: AKBA) and Innovative Renal Care (IRC) announced the nationwide availability of Vafseo® (vadadustat) across IRC's network of over 230 dialysis centers in 28 states and Washington, D.C. The treatment is now accessible to eligible patients among IRC's 16,000+ patient base.
Vafseo, FDA-approved in March 2024 for treating anemia due to chronic kidney disease in adults on dialysis for at least three months, became commercially available in January 2025. The drug is now accessible to over 55,000 patients through dialysis provider protocols, with expected expansion to reach 275,000 patients by Q4 2025.
Akebia Therapeutics (Nasdaq: AKBA) reported strong Q2 2025 financial results, highlighted by total net product revenues of $60.5 million. The company's newly launched anemia drug Vafseo® (vadadustat) generated $13.3 million in net product revenue, with prescription demand growing 55% over Q1. Auryxia® sales contributed $47.2 million.
Key developments include DaVita's operational pilot of Vafseo across 100+ dialysis clinics starting August 2025, completed enrollment in the VOICE trial with 2,116 patients, and initiation of the VOCAL trial for three-times-weekly dosing evaluation. The company achieved profitability with a net income of $0.2 million, compared to an $8.6 million loss in Q2 2024, and maintained a strong cash position of $137.3 million.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in Canaccord Genuity's 45th Annual Growth Conference. The company's CEO, John P. Butler, will engage in a Fireside Chat on Wednesday, August 13 at 1:30 PM EDT.
The conference is scheduled for August 12-14, 2025 in Boston. Investors can access the presentation webcast through the Investors section of Akebia's website after the conference.
Akebia Therapeutics (Nasdaq: AKBA) has launched the VOCAL trial, a post-marketing study for its FDA-approved anemia treatment Vafseo® (vadadustat). The study, conducted in partnership with DaVita clinics, will evaluate the benefits of three-times-weekly Vafseo dosing compared to standard erythropoiesis-stimulating agents (ESA) in dialysis patients.
The trial will enroll approximately 350 patients across 18 DaVita hemodialysis clinics for up to 33 weeks. The study includes a sub-study of 28 patients to analyze red blood cell quality. Primary endpoints focus on hemoglobin changes, while secondary endpoints include serious adverse events, target hemoglobin achievement, and RBC transfusion requirements.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four new employees as employment inducements. The options total 238,500 shares with an exercise price of $3.69 per share, matching the closing price on July 31, 2025.
The options will vest over a 4-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Akebia.
Akebia Therapeutics (Nasdaq: AKBA) has scheduled the release of its second quarter 2025 financial results for Thursday, August 7, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the results and recent business developments.
Participants are encouraged to register in advance and join the call 15 minutes early to ensure timely connection. The presentation will be accessible via live webcast through Akebia's investor relations website, with an archived version available for later viewing.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Chief Commercial Officer Nik Grund will engage in a Fireside Chat on Monday, July 14 at 10:00 AM EDT.
Investors and interested parties can access the presentation recording through the Investors section of Akebia's website at ir.akebia.com after the conference concludes.